KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data.

Julian Panés, Marla C Dubinsky, Yoh Ishiguro, Nidhi Shukla, Elena Dubcenco, Valencia Remple, Dolly Sharma, Remo Panaccione

J Crohns Colitis 19(7) jjaf095

PMID40488552
PMCIDPMC12260494
DOI10.1093/ecco-jcc/jjaf095
发表日期2025-06-09
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:非 KM 图;Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:AI 判定为 other;Figure 4.:生活质量量表图。
摘要

摘要

BACKGROUND AND AIMS: Comprehensive disease control is an important yet elusive treatment goal in ulcerative colitis (UC). We evaluated the effect of upadacitinib induction and maintenance treatment on composite clinical endpoints and normalization of important health-related quality of life (HRQoL) outcomes. METHODS: Data from the U-ACHIEVE and U-ACCOMPLISH trials were analyzed. Clinical responders to upadacitinib 45 mg 8-week induction were re-randomized 1:1:1 to upadacitinib 30 mg, 15 mg, or placebo for 52 weeks of maintenance. The percentage of patients achieving a composite clinical endpoint (clinical remission, complete symptom resolution, and Inflammatory Bowel Disease Questionnaire [IBDQ] remission) and a composite endpoint for normalization of HRQoL outcomes (Functional Assessment of Chronic Illness Therapy-Fatigue, IBDQ remission, Work Productivity and Activity Impairment Questionnaire-Ulcerative Colitis, 36-item Short Form Survey Physical Component Summary and Mental Component Survey, and EuroQol 5-Dimension 5-Level scores) was evaluated. RESULTS: At induction week 8, more patients treated with upadacitinib 45 mg achieved the composite clinical endpoint vs placebo (6.4% vs 0.9%, P ≤ .001) and normalization of the composite HRQoL endpoint (18.9% vs 5.5%, P ≤ .001). At maintenance week 52, the composite clinical endpoint was achieved by 18.3% and 13.1% of patients treated with upadacitinib 30 mg and 15 mg, respectively, vs 4.5% with placebo (P ≤ .001). Normalization of the composite HRQoL endpoint was achieved by 24.0% and 22.3% of patients treated with upadacitinib 30 mg and 15 mg, respectively, vs 8.7% for placebo (P ≤ .001). CONCLUSIONS: Upadacitinib may help patients with moderately to severely active UC achieve complete symptom resolution, endoscopic remission, and normalization of HRQoL. CLINICAL REGISTRATION NUMBERS: U-ACHIEVE (NCT02819635) and U-ACCOMPLISH (NCT03653026).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical Abstract无图注
非 KM Figure
Figure 1.Percentage of patients who achieved the composite endpoint of endoscopic remission, complete symptom resolution, and IBDQ remission at (A) induction week 8 and (B) maintenance weeks 0 and 52. *** p ≤ 0.001 for upadacitinib (UPA) versus placebo (PBO).
非 KM Figure
Figure 2.(A) Percentage of patients who achieved the composite clinical endpoint of endoscopic remission, complete symptom resolution, and IBDQ remission at maintenance week 52 among those who achieved the composite clinical endpoint at maintenance week 0. (B) Percentage of patients who achieved the composite clinical endpoint of endoscopic remission, complete symptom resolution, and IBDQ remission at maintenance week 52 among those who did not achieve the composite clinical endpoint at maintenance week 0. *** p ≤ 0.001 for upadacitinib (UPA) versus placebo (PBO).
非 KM Figure
Figure 3.Percentage of patients who achieved the composite clinical endpoint of endoscopic remission, complete symptom resolution, and IBDQ remission at (A) induction week 8 and (B) maintenance week 52 stratified by prior biologic use at induction baseline. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 for upadacitinib (UPA) versus placebo (PBO)..
非 KM Figure
Figure 4.Percentage of patients achieving normalization of the composite HRQoL endpoint with upadacitinib treatment at (A) induction week 8 and (B) maintenance week 52. *** p ≤ 0.001 for upadacitinib (UPA) versus placebo (PBO).
非 KM Figure